The ACI Summit on Biosimilars is the industry’s one and only event directed to the legal, regulatory and commercial aspects of the biosimilars marketplace. The speaking faculty will consist of top innovator and biosimilar makers, government representatives and leading law firms as they discuss the hottest industry challenges and provide their skilled insights into the design and execution of successful biosimilars strategies.

WilmerHale Partner Kevin Prussia will speak on the “The ITC: Examining the Role of this Alternate Forum in Biosimilars Disputes” panel. Panelists will expand on:

• Exploring the ITC as a venue for reaching a relatively swifter and earlier resolution of a biosimilars challenge
  • Weighing the pros and cons of avoiding the patent dance and assessing the benefits of asserting any number of claims in lieu of the aBLA process
• Capitalizing on the benefit of receiving remedies beyond the restrictions imposed by the district courts